Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Infiltration of human cancers by T cells is generally interpreted as a sign of immune
recognition, and there is a growing effort to reactivate dysfunctional T cells at such tumor …

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …

Detection of lymphocytes that target tumor-specific mutant neoantigens—derived from
products encoded by mutated genes in the tumor—is mostly limited to tumor-resident …

Accumulating evidence suggests that clinically efficacious cancer immunotherapies are
driven by T cell reactivity against DNA mutation–derived neoantigens. However, among the …

Background The T-cell receptor (TCR), located on the surface of T cells, is responsible for
the recognition of the antigen-major histocompatibility complex, leading to the initiation of an …

We developed TraCeR, a computational method to reconstruct full-length, paired T cell
receptor (TCR) sequences from T lymphocyte single-cell RNA sequence data. TraCeR links …

The immune system can mount T cell responses against tumors; however, the antigen
specificities of tumor-infiltrating lymphocytes (TILs) are not well understood. We used yeast …

Adoptive transfer of receptor-engineered T cells has produced impressive results in treating
patients with B cell leukemias and lymphomas. This success has captured public …